Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Case-control study learning module: Oluweafemi et al. (2026), The association between paternal race and ethnicity and a spectrum of birth defects in a national case-control study.

Annals of epidemiology·2026

Same author

Characteristics Associated with HIV Pre-Exposure Prophylaxis Persistence Among Men Who Have Sex with Men in the United States: Results from the American Men's Internet Survey, 2023-2024.

AIDS patient care and STDs·2026

Same author

Estimating modern US social contact patterns, the ENGAGED study: a study protocol for a staggered longitudinal cohort study.

BMJ open·2026

Same author

A Randomized Controlled Trial of the My Personal Health Guide Mobile Phone App on ART Adherence Among Young African American Men Who Have Sex With Men Living With HIV in the United States.

Open forum infectious diseases·2026

Same author

Economic Impact of Delaying the Infant Hepatitis B Vaccination Schedule.

JAMA pediatrics·2026

Same author

Alignment Between HIV Vulnerability and Pre-exposure Prophylaxis Use in a Longitudinal Study of Young, Black Men Who Have Sex with Men.

AIDS and behavior·2026

Same journal

Error in Byline.

JAMA network open·2026

Same journal

Error in Abstract.

JAMA network open·2026

Same journal

One Step Closer to Real-Time Detection of Missed Opportunities for Diagnosis in the ED Using LLMs.

JAMA network open·2026

Same journal

Procalcitonin-An Enigmatic Anxiolytic Biomarker.

JAMA network open·2026

Same journal

Terminated, Withdrawn, or Suspended Suicide Prevention Studies.

JAMA network open·2026

Same journal

Life's Essential 8 in Pregnancy and Time to Incident Cardiometabolic Disease Over 7 Years Follow-Up.

JAMA network open·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years.

Shi Hao Ernest Koh¹, Wenting Huang¹, Eric W Hall²

¹Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.

JAMA Network Open

|June 26, 2026

Summary

This summary is machine-generated.

Long-acting injectable cabotegravir (LAI-CAB) shows promise for HIV prevention, but its uptake remains low. Persistence with LAI-CAB and overall pre-exposure prophylaxis (PrEP) declines by year two, indicating a need for structural support to improve its use.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 28, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

Pharmacology and Pharmaceutics
Infectious Disease Epidemiology
Public Health Interventions

Background:

Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) offers superior efficacy compared to oral PrEP for HIV prevention.
Optimizing the impact of LAI-cabotegravir (CAB) hinges on achieving higher drug persistence among users.

Purpose of the Study:

To characterize users of LAI-CAB in comparison to oral PrEP.
To describe the trends in national LAI-CAB versus oral PrEP utilization over time.
To examine the longitudinal persistence rates among individuals using LAI-CAB.

Main Methods:

A retrospective cohort study utilizing national pharmacy and medical claims data from 2022 to 2024.
Inclusion criteria: individuals with at least one claim for any PrEP medication (oral or injectable).
Outcomes assessed: LAI-CAB use, LAI-CAB yearly persistence, and overall PrEP persistence, analyzed using multivariable logistic regression.

Main Results:

LAI-CAB represented 3% of all PrEP users (24,194/781,040) from 2022-2024, increasing to 4% by late 2024.
LAI-CAB users were younger, predominantly male, and more likely to have Medicaid coverage compared to oral PrEP users.
One-year persistence was approximately 50% for LAI-CAB and 57% for overall PrEP among LAI-CAB users, declining to 23% and 30% by year two, respectively. Lower persistence was observed in female users.

Conclusions:

LAI-CAB use constitutes a small fraction of the overall PrEP landscape in the US.
Persistence rates for both LAI-CAB and overall PrEP decrease significantly by the second year of use.
Effective scale-up of highly efficacious PrEP modalities like LAI-CAB requires integrated structural supports and behavioral interventions beyond implementation alone.